Motley Fool: Pfizer and Merck are keeping the Dow alive

Featured Story

Motley Fool: Pfizer and Merck are keeping the Dow alive

February 15, 2014 4:25 am by | 0 Comments

Pharmaceutical giant Pfizer Inc., which has its largest worldwide research site in Groton, is the third best-performing company so far this year among the 30 bellwether stocks that comprise the Dow Jones Industrial Average.
According to an article titl…


Merck opens office in technology innovation hub

Merck opens office in technology innovation hub

July 11, 2014 4:50 pm by | 0 Comments

On a recent tour of the latest addition to University City Science Center’s campus in Philadelphia – an innovation hub in an established building on its campus set to officially…


Merck drug for chemotherapy nausea also effective in children in late-stage study

Merck drug for chemotherapy nausea also effective in children in late-stage study

June 30, 2014 10:25 am by | 0 Comments

(Reuters) – Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in…



Merck licenses Bionomics’ research program for Alzheimer’s-related cognitive dysfunction

Merck licenses Bionomics’ research program for Alzheimer’s-related cognitive dysfunction

June 24, 2014 8:16 am by | 0 Comments

Australian drug maker Bionomics Ltd (ASX:BNO) said yesterday it had signed an exclusive research collaboration and licence deal with US Merck & Co Inc (NYSE:MRK) for Bionomics’ BNC375 research programme…


Merck is building a diabetes registry

Merck is building a diabetes registry

June 16, 2014 8:05 am by | 0 Comments

With diabetes cases estimated to have reached 29 million, making it one of the most common and costly chronic conditions, there is a thirst for more information to add insights…


Merck makes a $3.9B move on Idenix to up its chances in the lucrative hepatitis C drug space

Merck makes a $3.9B move on Idenix to up its chances in the lucrative hepatitis C drug space

June 10, 2014 10:27 am by | 0 Comments

Healthcare company Merc (NYSE:MRK) reported on Monday the execution of a definitive agreement to acquire Idenix Pharmaceuticals (NasdaqGS:IDIX) for USD24.50 per share in cash. The transaction, which is valued at…


Merck study finds poor compliance with allergen immunotherapy

Merck study finds poor compliance with allergen immunotherapy

June 5, 2014 12:17 pm by | 0 Comments

NEW YORK (Reuters Health) – Doctors may recommend allergy shots or under-the-tongue drops to their patients, but most don’t start the treatments, reports a new study. Researchers also found that…


Merck’s PD-1 inhibitor lives up to its hype in early melanoma, lung cancer trials

Merck’s PD-1 inhibitor lives up to its hype in early melanoma, lung cancer trials

June 2, 2014 4:34 pm by | 0 Comments

(Reuters) – A highly anticipated new immunotherapy from Merck & Co Inc proved effective in patients with advanced melanoma as well as some with lung cancer or head and neck…



Wellframe’s personalized care plan tool gets validation from Merck

Wellframe’s personalized care plan tool gets validation from Merck

May 14, 2014 11:49 am by | 0 Comments

Wellframe, a health IT company that’s developed a cloud-based platform to personalize care plans for people with chronic conditions, won an innovation challenge set down by Merck and Heritage Provider…


After safety concerns cause delays, Merck wins FDA approval for blood clot prevention drug

After safety concerns cause delays, Merck wins FDA approval for blood clot prevention drug

May 9, 2014 9:29 am by | 0 Comments

(Reuters) – U.S. health regulators on Thursday approved a blood clot preventer developed by Merck & Co for use by patients who have had a heart attack or who suffer…


Merck: We’ll seek FDA approval for delayed osteoporosis, post-anesthesia drugs this year

Merck: We’ll seek FDA approval for delayed osteoporosis, post-anesthesia drugs this year

May 6, 2014 5:00 pm by | 0 Comments

(Reuters) – Merck & Co said on Tuesday it plans to seek marketing approvals this year for an osteoporosis drug and a product to reverse the effects of anesthesia that…


Bayer to become 2nd-biggest OTC drug maker with $14B Merck Consumer Health acquisition

Bayer to become 2nd-biggest OTC drug maker with $14B Merck Consumer Health acquisition

May 6, 2014 7:48 am by | 0 Comments

(Reuters) – Merck & Co Inc has agreed to sell its consumer care business to Germany’s Bayer AG for $14.2 billion, the companies said on Tuesday, adding to a string…


ICYMI: Here are the 5 top stories in March on MedCity News

ICYMI: Here are the 5 top stories in March on MedCity News

March 31, 2014 4:29 pm by | 0 Comments

5. Now that’s a security breach: England’s entire healthcare data set uploaded to Google servers @JuliaHCox @CLeslieMP so HES data uploaded to ‘google’s immense army of servers’ , who consented…


Tech PR firm takes on Merck to save the life of an employee with kidney cancer

Tech PR firm takes on Merck to save the life of an employee with kidney cancer

March 23, 2014 12:00 pm by | 0 Comments

Last November, Mikaela Knapp was diagnosed with an aggressive strain of kidney cancer, which metastasized to her brain. Knapp is 25. Prior to her diagnosis, Knapp had worked as an account…


Merck digital health arm hopes to generate big data healthcare insights

Merck digital health arm hopes to generate big data healthcare insights

March 10, 2014 5:55 am by | 2 Comments

It’s been more than one year since Merck (NYSE: MRK) launched a digital health arm to develop big data insights in healthcare to guide therapies and develop patient-centered outcomes. CMIO…


Bayer, Novartis, others interested in Merck’s consumer healthcare unit

Bayer, Novartis, others interested in Merck’s consumer healthcare unit

February 19, 2014 4:12 pm by | 0 Comments

NEW YORK/LONDON (Reuters) – A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc’s consumer healthcare business, as they…